Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Language
Publication year range
1.
Braz J Med Biol Res ; 52(7): e8222, 2019.
Article in English | MEDLINE | ID: mdl-31291381

ABSTRACT

Monoclonal gammopathy of renal significance (MGRS) can present with different morphologic features and lead to kidney failure. The Henoch-Schönlein purpura nephritis (HSPN) that cannot be relieved by treatment with glucocorticoid and immunosuppressive agents suggests the presence of monoclonal gammopathy in adult patients. The present study reports on a single case of HSPN associated with IgA-κMGRS. The patient who suffered from recurrent skin purpura for 6 months and nephrotic syndrome for 2 months was admitted to our hospital. Bone marrow biopsy showed monoclonal gammopathy of undetermined significance. Kidney biopsy indicated a Henoch-Schönlein purpura nephritis (HSPN, ISKDC classified as type III) with positive staining with κ-light chain in the glomeruli and renal tubular epithelial cells. Furthermore, skin biopsy showed leukocytoclastic vasculitis and negative staining for Congo red and light chain. Given both the renal and cutaneous involvement, the patient was considered to have HSPN associated with IgA-κMGRS. The patient experienced an exacerbation in his purpura-like lesions and clinical status after treatment with glucocorticoid and immunosuppressive agents. Consequently, the patient was put on a regimen that included dexamethasone (20 mg on the 1st, 4th, 8th, and 11th days of each month, iv) and bortezomib (2.4 mg on the 1st, 4th, 8th, and 11th days of each month, iv). Eight weeks after treatment, he had complete resolution of his cutaneous purpura and his biochemical parameters improved. The latent presence of MGRS in cases of HSPN should be considered in adult patients. Increased cognizance and correct treatment options could improve patient outcomes.


Subject(s)
IgA Vasculitis/complications , Nephritis/complications , Paraproteinemias/etiology , Glucocorticoids/administration & dosage , Humans , IgA Vasculitis/drug therapy , IgA Vasculitis/pathology , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Nephritis/drug therapy , Nephritis/pathology , Paraproteinemias/drug therapy , Paraproteinemias/pathology
2.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;52(7): e8222, 2019. graf
Article in English | LILACS | ID: biblio-1011591

ABSTRACT

Monoclonal gammopathy of renal significance (MGRS) can present with different morphologic features and lead to kidney failure. The Henoch-Schönlein purpura nephritis (HSPN) that cannot be relieved by treatment with glucocorticoid and immunosuppressive agents suggests the presence of monoclonal gammopathy in adult patients. The present study reports on a single case of HSPN associated with IgA-κMGRS. The patient who suffered from recurrent skin purpura for 6 months and nephrotic syndrome for 2 months was admitted to our hospital. Bone marrow biopsy showed monoclonal gammopathy of undetermined significance. Kidney biopsy indicated a Henoch-Schönlein purpura nephritis (HSPN, ISKDC classified as type III) with positive staining with κ-light chain in the glomeruli and renal tubular epithelial cells. Furthermore, skin biopsy showed leukocytoclastic vasculitis and negative staining for Congo red and light chain. Given both the renal and cutaneous involvement, the patient was considered to have HSPN associated with IgA-κMGRS. The patient experienced an exacerbation in his purpura-like lesions and clinical status after treatment with glucocorticoid and immunosuppressive agents. Consequently, the patient was put on a regimen that included dexamethasone (20 mg on the 1st, 4th, 8th, and 11th days of each month, iv) and bortezomib (2.4 mg on the 1st, 4th, 8th, and 11th days of each month, iv). Eight weeks after treatment, he had complete resolution of his cutaneous purpura and his biochemical parameters improved. The latent presence of MGRS in cases of HSPN should be considered in adult patients. Increased cognizance and correct treatment options could improve patient outcomes.


Subject(s)
Humans , Male , Middle Aged , Paraproteinemias/etiology , IgA Vasculitis/complications , Nephritis/complications , Paraproteinemias/pathology , Paraproteinemias/drug therapy , IgA Vasculitis/pathology , IgA Vasculitis/drug therapy , Glucocorticoids/administration & dosage , Immunosuppressive Agents/administration & dosage , Nephritis/pathology , Nephritis/drug therapy
3.
Ann. hepatol ; Ann. hepatol;16(3): 460-464, May.-Jun. 2017. graf
Article in English | LILACS | ID: biblio-887259

ABSTRACT

ABSTRACT The Abernethy malformation is a rare congenital malformation defined by the presence of an extrahepatic portosystemic shunt. Although most patients are asymptomatic, clinical encephalopathy is present in 15% of cases. We present a patient with type 2 Abernethy malformation, hyperammonemia, and encephalopathy. Shunt closure was performed successfully using interventional angiography; however, hyperammonemia recurred 3 months later. The diagnosis of Abernethy malformation can be made easily, but the ideal patient management strategy has not yet been established. This is the first reported patient with recurrence of hyperammonemia after interventional treatment; we discuss the therapeutic options for Abernethy malformation.(AU)


Subject(s)
Humans , Congenital Abnormalities/physiopathology , Brain Diseases/etiology , Hyperammonemia/etiology , Angiography/instrumentation , Portasystemic Shunt, Surgical
4.
Ann Hepatol ; 16(3): 460-464, 2017.
Article in English | MEDLINE | ID: mdl-28425418

ABSTRACT

The Abernethy malformation is a rare congenital malformation defined by the presence of an extrahepatic portosystemic shunt. Although most patients are asymptomatic, clinical encephalopathy is present in 15% of cases. We present a patient with type 2 Abernethy malformation, hyperammonemia, and encephalopathy. Shunt closure was performed successfully using interventional angiography; however, hyperammonemia recurred 3 months later. The diagnosis of Abernethy malformation can be made easily, but the ideal patient management strategy has not yet been established. This is the first reported patient with recurrence of hyperammonemia after interventional treatment; we discuss the therapeutic options for Abernethy malformation.


Subject(s)
Embolization, Therapeutic , Hyperammonemia/etiology , Mesenteric Veins/abnormalities , Portal Vein/abnormalities , Vascular Malformations/therapy , Computed Tomography Angiography , Female , Hepatic Encephalopathy/etiology , Humans , Hyperammonemia/diagnosis , Mesenteric Veins/diagnostic imaging , Middle Aged , Phlebography/methods , Portal Vein/diagnostic imaging , Radiography, Interventional , Recurrence , Treatment Outcome , Vascular Malformations/complications , Vascular Malformations/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL